Skip to main content
. 2019 Mar 18;3(5):620–631. doi: 10.1002/hep4.1334

Table 3.

Prevalence and Examples of MRPs Identified During the Study Period

n (%) Patients With ≥ 1 MRP* n (%) Instances of MRPs n (%) Instances of High‐Risk MRPs Examples of High‐Risk MRPs
Nonadherence 38 (66.7%) 118 (31.5%) 57 (48.3%)
Intentional 28 (49.1%) 77 (65.3%) 39 (50.6%) Nonadherence with diuretics in a patient with large volume ascites due to urinary urgency
Unintentional 14 (24.6%) 22 (18.6%) 9 (40.9%) Nonadherence with spontaneous bacterial peritonitis prophylaxis as the patient assumed antibiotics would cease after course completed
Other 12 (21.1%) 19 (16.1%) 9 (47.4%) Financial circumstance impacting adherence with lactulose in a patient with HE
Adverse drug reaction 18 (31.6%) 21 (5.6%) 12 (57.1%) Irritability and mood disturbances (on a background of depression and anxiety) while taking prednisolone prescribed for alcoholic hepatitis
Drug interactions 19 (33.3%) 24 (6.4%) 21 (87.5%)
Drug–drug 5 (8.8%) 5 (20.8%) 3 (60.0%) High‐dose tramadol and sertraline coadministration causing tremors, agitation, and sweating
Drug–disease 16 (28.1%) 19 (79.2%) 18 (94.7%) Use of NSAIDs by a patient with a history of ascites and renal impairment
Indication 47 (82.5%) 109 (29.1%) 34 (31.2%)
Wrong drug 14 (24.6%) 16 (14.7%) 12 (75.0%) Opioid‐naive patient prescribed a fentanyl patch for chronic pain by general practitioner
Unnecessary drug 15 (26.3%) 21 (19.3%) 3 (14.3%) Ongoing insulin use by a patient with hypoglycemia (previously started for elevated blood sugar levels while taking prednisolone)
Untreated indication 40 (70.2%) 72 (67.9%) 19 (26.4%) Constipation in a patient at risk of encephalopathy not prescribed lactulose or an alternative aperient
Suboptimal dose 31 (54.4%) 62 (16.5%) 41 (66.1%)
Dose too high 19 (33.3%) 30 (48.4%) 18 (60.0%) Significant diarrhea associated with high lactulose dose in a patient with a history of encephalopathy
Dose too low 23 (40.4%) 32 (51.6%) 23 (71.9%) Patient with moderate volume ascites intended to increase diuretics following prior review; however, dose change not made in Webster‐Pak
Monitoring issues 30 (52.6%) 41 (10.9%) 15 (36.6%) Pathology not requested for a patient restarted on diuretics for ascites, following recent hyponatremia and acute kidney injury

*Patients may have had an MRP in ≥1 subtype;

nonadherence due to financial or social circumstance.